Literature DB >> 29904429

Effect of dexmedetomidine, midazolam, and propofol on lipopolysaccharide-stimulated dendritic cells.

Feng Guo1, Ying Ding2, Xue Yu3, Xiujun Cai4.   

Abstract

Dexmedetomidine, midazolam and propofol are common sedative drugs used in the intensive care unit. Lipopolysaccharides (LPS) are a potent inducer of human dendritic cells (DCs) maturation and survival, which induces cytokine production. The present study aimed to investigate the effect and mechanisms of sedative drugs on LPS-induced cytokine production in DCs. The mouse bone marrow-derived dendritic DC2.4 cell line was used in the present study. The Cell Counting Kit-8 assay was used to measure the viability of cells. Tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, and IL-10 mRNA expression levels and contents were measured using reverse transcription-quantitative polymerase chain reaction and ELISA, respectively. The expression levels of proteins associated with nuclear factor-κB (NF-κB) and mitogen activated protein kinase signaling pathways were assessed by western blotting. The three sedatives had different roles on TNF-α, IL-1β, IL-6, and IL-10 mRNA expression levels and content in DCs. Dexmedetomidine promoted inflammatory cytokine production at high clinical concentrations (10, 1 and 0.1 µM), however suppressed them at the lowest clinical concentration (0.001 µM), which was associated with NF-κB and c-Jun N-terminal kinase (JNK)-mitogen-activated protein kinase (MAPK) signaling. Midazolam inhibited inflammatory cytokine production via suppression of the NF-κB and JNK signaling pathways. Propofol partly inhibited inflammatory cytokine production, including IL-1β and IL-6, and the anti-inflammatory effect may result from inhibition of JNK-MAPK, and enhanced NF-κB and extracellular signal-regulated kinase-MAPK signaling at clinical concentrations. The present study helped to elucidate the function of sedatives in LPS-induced cytokine production in DCs, which will facilitate rational implementation of these sedatives in patients undergoing tracheal intubation with sepsis or multiple organ dysfunction syndrome.

Entities:  

Keywords:  dendritic cells; dexmedetomidine; inflammation; midazolam; propofol

Year:  2018        PMID: 29904429      PMCID: PMC5996670          DOI: 10.3892/etm.2018.6094

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  39 in total

1.  Mycophenolic acid differentially affects dendritic cell maturation induced by tumor necrosis factor-alpha and lipopolysaccharide through a different modulation of MAPK signaling.

Authors:  Delphine Faugaret; Roxane Lemoine; Christophe Baron; Yvon Lebranchu; Florence Velge-Roussel
Journal:  Mol Immunol       Date:  2010-03-23       Impact factor: 4.407

2.  A comparative analysis of cytokine responses, cell surface marker expression and MAPKs in DCs matured with LPS compared with a panel of TLR ligands.

Authors:  David Dowling; Clare M Hamilton; Sandra M O'Neill
Journal:  Cytokine       Date:  2008-01-24       Impact factor: 3.861

3.  Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials.

Authors:  Stephan M Jakob; Esko Ruokonen; R Michael Grounds; Toni Sarapohja; Chris Garratt; Stuart J Pocock; J Raymond Bratty; Jukka Takala
Journal:  JAMA       Date:  2012-03-21       Impact factor: 56.272

4.  Dendritic cells infected with recombinant fowlpox virus vectors are potent and long-acting stimulators of transgene-specific class I restricted T lymphocyte activity.

Authors:  M Brown; Y Zhang; S Dermine; E A de Wynter; C Hart; H Kitchener; P L Stern; M A Skinner; S N Stacey
Journal:  Gene Ther       Date:  2000-10       Impact factor: 5.250

5.  Computer-controlled infusion of intravenous dexmedetomidine hydrochloride in adult human volunteers.

Authors:  J B Dyck; M Maze; C Haack; D L Azarnoff; L Vuorilehto; S L Shafer
Journal:  Anesthesiology       Date:  1993-05       Impact factor: 7.892

6.  Propofol reduces nitric oxide biosynthesis in lipopolysaccharide-activated macrophages by downregulating the expression of inducible nitric oxide synthase.

Authors:  Ruei-Ming Chen; Gong-Jhe Wu; Yi-Ting Tai; Wei-Zen Sun; Yi-Ling Lin; Wen-Chi Jean; Ta-Liang Chen
Journal:  Arch Toxicol       Date:  2003-03-12       Impact factor: 5.153

7.  Effects of propofol on the leukocyte nitric oxide pathway: in vitro and ex vivo studies in surgical patients.

Authors:  J A González-Correa; E Cruz-Andreotti; M M Arrebola; J A López-Villodres; M Jódar; J P De La Cruz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-12-07       Impact factor: 3.000

Review 8.  IL-1, IL-18, and IL-33 families of cytokines.

Authors:  William P Arend; Gaby Palmer; Cem Gabay
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

9.  Comparative effects of propofol vs dexmedetomidine on cerebrovascular carbon dioxide reactivity in patients with septic shock.

Authors:  Y Kadoi; S Saito; C Kawauchi; H Hinohara; F Kunimoto
Journal:  Br J Anaesth       Date:  2008-01-04       Impact factor: 9.166

10.  Suppression of phagosome proteolysis and Matrigel migration with the α2-adrenergic receptor agonist dexmedetomidine in murine dendritic cells.

Authors:  Hironobu Ueshima; Takefumi Inada; Koh Shingu
Journal:  Immunopharmacol Immunotoxicol       Date:  2013-08-08       Impact factor: 2.730

View more
  4 in total

1.  Propofol Prevents the Growth, Migration, Invasion, and Glycolysis of Colorectal Cancer Cells by Downregulating Lactate Dehydrogenase Both In Vitro and In Vivo.

Authors:  Zhichao Wu; Han Wang; Zu-An Shi; Yalan Li
Journal:  J Oncol       Date:  2022-04-30       Impact factor: 4.501

Review 2.  Effects of Dexmedetomidine on Immune Cells: A Narrative Review.

Authors:  Rui Chen; Yan Sun; Jing Lv; Xiaoke Dou; Maosha Dai; Shujun Sun; Yun Lin
Journal:  Front Pharmacol       Date:  2022-05-02       Impact factor: 5.810

3.  Anti-inflammatory effects of dexmedetomidine on human amnion-derived WISH cells.

Authors:  Sang-Hun Shin; Jae-Chaul You; Ji-Hye Ahn; Yeon Ha Kim; Ji-Uk Yoon; Ah-Reum Cho; Eun-Jung Kim
Journal:  Int J Med Sci       Date:  2020-09-09       Impact factor: 3.738

4.  Dexmedetomidine does not compromise neuronal viability, synaptic connectivity, learning and memory in a rodent model.

Authors:  Nerea Jimenez-Tellez; Fahad Iqbal; Marcus Pehar; Alberto Casas-Ortiz; Tiffany Rice; Naweed I Syed
Journal:  Sci Rep       Date:  2021-08-09       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.